Market closed
Vaxcyte/$PCVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Ticker
$PCVX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
414
Website
Vaxcyte Metrics
BasicAdvanced
$3.9B
-
-$3.80
0.98
-
Price and volume
Market cap
$3.9B
Beta
0.98
52-week high
$116.95
52-week low
$30.01
Average daily volume
2.1M
Financial strength
Current ratio
12.755
Quick ratio
12.611
Long term debt to equity
1.973
Total debt to equity
2.151
Management effectiveness
Return on assets (TTM)
-14.47%
Return on equity (TTM)
-20.41%
Valuation
Price to book
1.15
Price to tangible book (TTM)
1.15
Price to free cash flow (TTM)
-6.52
Growth
Earnings per share change (TTM)
-8.15%
3-year earnings per share growth (CAGR)
25.42%
What the Analysts think about Vaxcyte
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.
Vaxcyte Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Vaxcyte Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Vaxcyte News
AllArticlesVideos
$PCVX
NaN%Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Seeking Alpha·4 days ago
$PCVX
NaN%Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
GlobeNewsWire·5 days ago
$PCVX
NaN%Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vaxcyte stock?
Vaxcyte (PCVX) has a market cap of $3.9B as of April 05, 2025.
What is the P/E ratio for Vaxcyte stock?
The price to earnings (P/E) ratio for Vaxcyte (PCVX) stock is 0 as of April 05, 2025.
Does Vaxcyte stock pay dividends?
No, Vaxcyte (PCVX) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Vaxcyte dividend payment date?
Vaxcyte (PCVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxcyte?
Vaxcyte (PCVX) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
